To test whether saracatinib could also inhibit activin A–induced activation of SMAD1/5, we used primary dermal fibroblast cells derived from FOP patients with the classic ACVR1R206H mutation or WT control cells. This evidence concerns the gene SMAD1 and fibrodysplasia ossificans progressiva.